BioAffinity Technologies Inc
Research BioAffinity Technologies Inc (BIAF) on Bullrun: market cap USD 35.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIAF
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 35.20M
- Financial periodQ1 2026
- RevenueUSD 1.35M
- Net income-USD 3.63M
- Free cash flow-USD 3.23M
- Gross margin31.3%
Valuation Snapshot
latest market cap is USD 35.20M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 6.16M | -USD 14.91M | -USD 9.39M | 30.5% | -8.66 | USD 6.45M | USD 1.16M | USD 7.28M |
| FY2024 | USD 9.36M | -USD 9.04M | -USD 7.34M | 36.1% | -22.5 | USD 1.11M | USD 1.50M | USD 2.60M |
| FY2023 | USD 2.53M | -USD 7.94M | -USD 6.06M | 31.3% | -0.91 | USD 2.82M | USD 1.58M | USD 4.86M |
| FY2022 | USD 4.80K | -USD 8.15M | -USD 4.29M | 90.3% | -1.81 | USD 11.41M | USD 11.12M | USD 11.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 35.20M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.31M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 14.17M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 13.98M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.39M | n/a | n/a | n/a |
About BioAffinity Technologies Inc
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioAffinity Technologies Inc's market cap?
BioAffinity Technologies Inc's market capitalization is USD 35.20M.
What does BioAffinity Technologies Inc do?
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.